{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T22:38:08Z","timestamp":1788043088655,"version":"build-2784847793"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010408","name":"Polpharma Scientific Foundation","doi-asserted-by":"publisher","award":["1027.0641.36.2020"],"award-info":[{"award-number":["1027.0641.36.2020"]}],"id":[{"id":"10.13039\/501100010408","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010408","name":"Polpharma Scientific Foundation","doi-asserted-by":"publisher","award":["2020-2024"],"award-info":[{"award-number":["2020-2024"]}],"id":[{"id":"10.13039\/501100010408","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.bbrc.2026.153752","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T16:55:27Z","timestamp":1775753727000},"page":"153752","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Targeting BCL-2 and PI3K signaling pathways enhances cytotoxicity of gemtuzumab ozogamicin against acute myeloid leukemia cells"],"prefix":"10.1016","volume":"817","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8744-8451","authenticated-orcid":false,"given":"Malgorzata","family":"Opydo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malgorzata","family":"Wojtaszek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Mosurek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4336-9620","authenticated-orcid":false,"given":"Gabriela","family":"Burczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3075-5928","authenticated-orcid":false,"given":"Anna","family":"Such","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3573-3584","authenticated-orcid":false,"given":"Elzbieta","family":"Kolaczkowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2026.153752_bib1","first-page":"328","article-title":"Acute myeloid leukemia - genetic alterations and their clinical prognosis","volume":"11","author":"Lagunas-Rangel","year":"2017","journal-title":"Int. J. Hematol. Oncol. Stem Cell Res."},{"key":"10.1016\/j.bbrc.2026.153752_bib2","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1517\/14728222.2014.909413","article-title":"The role of CD33 as therapeutic target in acute myeloid leukemia","volume":"18","author":"Walter Rb","year":"2014","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.bbrc.2026.153752_bib3","doi-asserted-by":"crossref","first-page":"43281","DOI":"10.18632\/oncotarget.9674","article-title":"Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia","volume":"7","author":"Laszlo","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbrc.2026.153752_bib4","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.3390\/cancers13133214","article-title":"CD33 expression and gentuzumab ozogamicin in acute myeloid leukemia: two sides of the same coin","volume":"13","author":"Molica","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bbrc.2026.153752_bib5","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2014.39","article-title":"Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia","volume":"4","author":"Ehninger","year":"2014","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.bbrc.2026.153752_bib6","doi-asserted-by":"crossref","first-page":"6198","DOI":"10.1182\/blood-2011-11-325050","article-title":"Acute myeloid leukemia stem cells and CD33-targeted immunotherapy","volume":"119","author":"Walter","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2026.153752_bib7","doi-asserted-by":"crossref","first-page":"9107","DOI":"10.1038\/sj.onc.1207196","article-title":"Induction of apoptosis by enediyne antibiotic calicheamicin thetaII proceeds through a caspase-mediated mitochondrial amplification loop in an entirely Bax-dependent manner","volume":"22","author":"Prokop","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.bbrc.2026.153752_bib8","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/s41419-019-1407-6","article-title":"BCL-2 family isoforms in apoptosis and cancer","volume":"10","author":"Warren","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbrc.2026.153752_bib9","first-page":"169","article-title":"Targeted therapy with a selective BCL-2 inhibitor in older patients with acute myeloid leukemia, Hematol. Transfus","volume":"41","author":"Vale Camposa","year":"2019","journal-title":"Cell Ther."},{"key":"10.1016\/j.bbrc.2026.153752_bib10","doi-asserted-by":"crossref","DOI":"10.1098\/rsob.180002","article-title":"Targeting BCL-2 regulated apoptosis in cancer","volume":"8","author":"Campbell","year":"2018","journal-title":"Open Biol."},{"key":"10.1016\/j.bbrc.2026.153752_bib11","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/sj.leu.2402090","article-title":"Phosphorylation of Bcl2 and regulation of apoptosis","volume":"15","author":"Ruvolo","year":"2001","journal-title":"Leukemia"},{"key":"10.1016\/j.bbrc.2026.153752_bib12","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/sj.leu.2404245","article-title":"Phosphoinositide 3-kinase\/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia","volume":"20","author":"Martelli","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.bbrc.2026.153752_bib13","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.3390\/ijms21082907","article-title":"The PI3K-Akt-mTOR signaling pathway in human acute myeloid leukemia (AML) cells","volume":"21","author":"Nepstad","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrc.2026.153752_bib14","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s43018-020-00165-6","article-title":"A venetoclax bench-to-bedside story","volume":"2","author":"DiNardo","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.bbrc.2026.153752_bib15","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1182\/blood-2004-07-2784","article-title":"Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin\u2013induced cytotoxicity","volume":"105","author":"Walter","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2026.153752_bib16","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1182\/blood.V97.10.3197","article-title":"Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells","volume":"97","author":"van der Velden","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2026.153752_bib17","doi-asserted-by":"crossref","first-page":"7180","DOI":"10.3390\/ijms24087180","article-title":"Synergistic action of MCL-1 inhibitor with BCL-2\/BCL-XL or MAPK pathway inhibitors enhances acute myeloid leukemia cell apoptosis and differentiation","volume":"24","author":"Opydo","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrc.2026.153752_bib18","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.pharmthera.2019.04.008","article-title":"Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates","volume":"200","author":"Mahalingaiah","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bbrc.2026.153752_bib19","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2014.525","article-title":"MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K\/AKT\/mTOR activation in lymphoid malignancies","volume":"6","author":"Choudhary","year":"2015","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbrc.2026.153752_bib20","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1038\/s41375-020-0710-7","article-title":"Low-frequency TP53 hotspot mutation contributes to chemoresistance through clonal expansion in acute myeloid leukemia","volume":"34","author":"Yan","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.bbrc.2026.153752_bib21","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.2217\/fon-2018-0325","article-title":"Gemtuzumab ozogamicin for treatment of newly diagnosed CD33-positive acute myeloid leukemia","volume":"14","author":"Gbadamosi","year":"2018","journal-title":"Future Oncol."},{"key":"10.1016\/j.bbrc.2026.153752_bib22","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1182\/blood-2002-07-2311","article-title":"Differential response of human acute myeloid leukemia cells to gemtuzumab ozogamicin in vitro: role of Chk1 and Chk2 phosphorylation and caspase 3","volume":"101","author":"Amico","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2026.153752_bib23","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood.V114.22.2745.2745","article-title":"Distinct signaling profiles of gemtuzumab ozogamicin responsiveness and refractoriness in acute myeloid leukemia","volume":"114","author":"Rosen","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2026.153752_bib24","article-title":"CD33_PGx6_score predicts gemtuzumab ozogamicin response in childhood acute myeloid leukemia: a report from the children's oncology group","volume":"3","author":"Chauhan","year":"2019","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.bbrc.2026.153752_bib25","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3390\/cancers15030713","article-title":"Mechanisms of ADC toxicity and strategies to increase ADC tolerability","volume":"15","author":"Nguyen","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.bbrc.2026.153752_bib26","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/sj.leu.2403205","article-title":"Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity","volume":"18","author":"Jedema","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.bbrc.2026.153752_bib27","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/S1471-4892(03)00083-3","article-title":"Antibody-targeted chemotherapy with immunoconjugates of calicheamicin","volume":"3","author":"Damle","year":"2003","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.bbrc.2026.153752_bib28","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1080\/10428194.2020.1786553","article-title":"Anti-apoptotic BCL-2 family proteins confer resistance to calicheamicin-based antibody-drug conjugate therapy of acute leukemia","volume":"61","author":"Godwin","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.bbrc.2026.153752_bib29","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.3892\/ijo_00000638","article-title":"Multidrug transporter proteins and cellular factors involved in free and mAb linked calicheamicin-\u03b31 (gentuzumab ozogamicin, GO) resistance and in the selection of GO resistant variants of the HL60 AML cell line","volume":"36","author":"Cianfriglia","year":"2010","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.bbrc.2026.153752_bib30","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ccr.2006.03.027","article-title":"Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members","volume":"9","author":"Certo","year":"2006","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbrc.2026.153752_bib31","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1126\/science.1206727","article-title":"Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy","volume":"334","author":"Chonghaile","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2026.153752_bib32","first-page":"1253","article-title":"BH3 profiling as pharmacodynamic biomarker for the activity of BH3 mimetics","volume":"109","author":"Pan","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.bbrc.2026.153752_bib33","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood.V104.11.865.865","article-title":"Phase 2 study of oblimersen sodium (G3139; Bcl-2 Antisense; Genasense\u00ae) plus gemtuzumab ozogamicin (Mylotarg\u00ae) in elderly patients with relapsed acute myeloid leukemia (AML)","volume":"104","author":"Moore","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2026.153752_bib34","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.leukres.2005.10.025","article-title":"A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse","volume":"30","author":"Moore","year":"2006","journal-title":"Leuk. Res."},{"key":"10.1016\/j.bbrc.2026.153752_bib35","doi-asserted-by":"crossref","first-page":"3949","DOI":"10.3390\/cancers13163949","article-title":"The pathogenic role of PI3K\/AKT pathway in cancer onset and drug resistance: an updated review","volume":"13","author":"Rascio","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bbrc.2026.153752_bib36","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1182\/blood-2002-11-3429","article-title":"Survival of acute myeloid leukemia cells requires PI3 kinase activation","volume":"102","author":"Xu","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2026.153752_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0053518","article-title":"AKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicin","volume":"8","author":"Rosen","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bbrc.2026.153752_bib38","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrc3538","article-title":"Decoding and unlocking the BCL-2 dependency of cancer cells","volume":"13","author":"Juin","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbrc.2026.153752_bib39","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/leu.2011.46","article-title":"Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K\/PTEN\/Akt\/mTOR pathway","volume":"25","author":"Martelli","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.bbrc.2026.153752_bib40","doi-asserted-by":"crossref","first-page":"35202","DOI":"10.18632\/oncotarget.6051","article-title":"MCL-1-independent mechanisms of synergy between dual PI3K\/mTOR and BCL-2 inhibition in diffuse large B cell lymphoma","volume":"6","author":"Lee","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbrc.2026.153752_bib41","article-title":"Targeting MCL-1\/BCL-XL forestalls the acquisition of resistance to ABT-199 in acute myeloid leukemia","volume":"6","author":"Lin","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbrc.2026.153752_bib42","first-page":"5481","article-title":"A-1210477, a selective MCL-1 inhibitor, overcomes ABT-737 resistance in AML","volume":"18","author":"Wang","year":"2019","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.bbrc.2026.153752_bib43","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.3390\/cancers11121983","article-title":"p53-mediated tumor suppression: DNA-damage response and alternative mechanisms","volume":"11","author":"Pitolli","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.bbrc.2026.153752_bib44","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3389\/fonc.2019.00057","article-title":"Chk1 inhibition restores Inotuzumab Ozogamicin citotoxicity in CD22-positive cells expressing mutant p53","volume":"9","author":"Tirr\u00f2","year":"2019","journal-title":"Front. Oncol."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X26005164?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X26005164?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T15:38:47Z","timestamp":1777390727000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X26005164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":44,"alternative-id":["S0006291X26005164"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2026.153752","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting BCL-2 and PI3K signaling pathways enhances cytotoxicity of gemtuzumab ozogamicin against acute myeloid leukemia cells","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2026.153752","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"153752"}}